Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Medtronic
Moodys
Baxter
Harvard Business School

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

MINASTRIN 24 FE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Minastrin 24 Fe patents expire, and what generic alternatives are available?

Minastrin 24 Fe is a drug marketed by Apil and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in MINASTRIN 24 FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Drug patent expirations by year for MINASTRIN 24 FE
Recent Litigation for MINASTRIN 24 FE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Teva Women's Health, Inc. v. Famy Care Ltd.2014-12-05
Warner Chilcott Company, LLC v. Lupin Ltd.2014-01-27
Bayer Intellectual Property GMBH v. Warner Chilcott Company LLC2012-08-13

See all MINASTRIN 24 FE litigation

Synonyms for MINASTRIN 24 FE
19-Nor-17-alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate mixed with 19-nor-17-alpha-pregna-1,3,5-(10)-trien-20-yne-3,17-diol
8015-12-1
8067-81-0
AC1L1Y7Y
Anovlar 21
Aurovela 1.5/30
Controvlar
Cumorit
Econ 30
ESTROSTEP 21
Etalontin
Ethinyl estradiol mixture with norethindrone acetate
Ethinyl oestradiol mixed with norethisterone acetate
Ethinylestradiol and norethindrone acetate
Gyn-Anovlar
Gynonlar
Gynonlar 21
Hailey Fe 1/20
Junel 1.5/30
Junel 1/20
Lo Loestrin
Lo Loestrin Fe
LOESTRIN 21 1.5/30
LOESTRIN 21 1/20
LOESTRIN FE 1/20
Microgestin
Microgestin 1.5/30
Microgestin 1/20
Neorlest
Norethindrone acetate and ethinyl estradiol
Norethindrone acetate and ethinylestradiol
Norethisterone acetate mixed with ethinyl oestradiol
NORLESTRIN 21 1/50
NORLESTRIN 21 2.5/50
NORLESTRIN 28 1/50
Primodos
SCHEMBL2523461
Sinovula
Taytulla
Trentovlane
Tri-legest 21
Paragraph IV (Patent) Challenges for MINASTRIN 24 FE
Tradename Dosage Ingredient NDA Submissiondate
MINASTRIN 24 FE TABLET, CHEWABLE;ORAL ethinyl estradiol; norethindrone acetate 203667 2014-04-23

US Patents and Regulatory Information for MINASTRIN 24 FE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil MINASTRIN 24 FE ethinyl estradiol; norethindrone acetate TABLET, CHEWABLE;ORAL 203667-001 May 8, 2013 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MINASTRIN 24 FE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil MINASTRIN 24 FE ethinyl estradiol; norethindrone acetate TABLET, CHEWABLE;ORAL 203667-001 May 8, 2013   Start Trial   Start Trial
Apil MINASTRIN 24 FE ethinyl estradiol; norethindrone acetate TABLET, CHEWABLE;ORAL 203667-001 May 8, 2013   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Mallinckrodt
Merck
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.